Sumitomo Pharma America, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1984-01-01

Employees: 5K

Market Cap: -

Website: http://www.sunovion.com

Clinical Trials

Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With Insomnia

Phase 3

Completed

Conditions: Primary Insomnia

Interventions: Drug: placebo
Drug: eszopiclone 3 mg

First Posted Date: 2012-10-19

Last Posted Date: 2012-10-22

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 791

Registration Number: NCT01710631

Adult Attention Deficit Hyperactivity Disorder

Phase 2

Completed

Conditions: Adult Attention Deficit Hyperactivity Disorder

Interventions: Drug: SEP-225289
Drug: Placebo

First Posted Date: 2012-09-25

Last Posted Date: 2015-01-12

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 341

Registration Number: NCT01692782

Locations: 🇺🇸
University of California at Irvine, Irvine, California, United States
🇺🇸
Collaborative Neuroscience Network Inc, Garden Grove, California, United States
🇺🇸
Excell Research, Inc, Oceanside, California, United States

and more 26 locations

A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: levalbuterol 90 mcg
Drug: levalbuterol 180 mcg
Drug: racemic albuterol 180 mcg
Drug: Placebo

First Posted Date: 2012-08-03

Last Posted Date: 2012-08-03

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 146

Registration Number: NCT01656811

A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)

Phase 4

Completed

Conditions: Perennial Allergic Rhinitis

Interventions: Drug: ciclesonide nasal aerosol
Drug: ciclesonide nasal spray

First Posted Date: 2012-07-31

Last Posted Date: 2014-07-24

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 737

Registration Number: NCT01654536

Locations: 🇺🇸
Kerrville Research Associates, PA, Kerrville, Texas, United States
🇺🇸
Clinical Research Group of Montanta, Bozeman, Montana, United States
🇺🇸
Valley Clinical Research Center, Bethlehem, Pennsylvania, United States

and more 28 locations

Clinical Study of WT2725 in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Cancer

Interventions: Biological: WT2725

First Posted Date: 2012-06-18

Last Posted Date: 2019-07-17

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 64

Registration Number: NCT01621542

Locations: 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

and more 3 locations

Lurasidone Pediatric Pharmacokinetics Study

Phase 1

Completed

Conditions: Schizophrenia
Autism

Interventions: Drug: Lurasidone

First Posted Date: 2012-06-15

Last Posted Date: 2016-04-08

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 105

Registration Number: NCT01620060

Locations: 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸
Woodland International Research Group, Inc., Little Rock, Arkansas, United States
🇺🇸
Woodland Northwest Research, LLC, Springdale, Arkansas, United States

and more 7 locations

This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296

Phase 3

Completed

Conditions: Bipolar I Disorder

Interventions: Drug: Lurasidone

First Posted Date: 2012-04-11

Last Posted Date: 2016-08-22

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 377

Registration Number: NCT01575561

Locations: 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸
Psychoneuroendocrinology Research Group, Dept of Psychiatry, UT Southwestern Medical Center, Dallas, Texas, United States
🇵🇱
NZOZ BioMed, Kielce, Poland

and more 65 locations

A Twelve Week, Open Label Extension Study in Patients With Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Lurasidone

First Posted Date: 2012-03-29

Last Posted Date: 2019-04-09

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 191

Registration Number: NCT01566162

Locations: 🇺🇸
AXIS Clinical Trials, Los Angeles, California, United States
🇺🇸
CNRI-Los Angeles. LLC, Pico Rivera, California, United States
🇺🇸
Neuropsychiatric Research Center of Orange County, Santa Ana, California, United States

and more 59 locations

A Phase 1, Open-Label, Single-photon Emission Computed Tomography (SPECT) Study to Evaluate Serotonin and Dopamine Transporter Occupancy After Multiple Dose Administration of SEP-228432 to Achieve Steady State in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: SEP-228432

First Posted Date: 2012-02-13

Last Posted Date: 2013-12-09

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 30

Registration Number: NCT01531972

Locations: 🇺🇸
Molecular NeuroImaging, New Haven, Connecticut, United States

Lurasidone Extended Use Study

Phase 3

Completed

Conditions: Schizophrenia
Bipolar Disorder

Interventions: Drug: Lurasidone

First Posted Date: 2011-12-05

Last Posted Date: 2016-11-04

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 162

Registration Number: NCT01485640

Locations: 🇷🇴
Spitalul Clinic de Neuropsihiatrie Craiova, Craiova, Romania
🇨🇿
Psychiatricka ambulance, Brno-mesto, Czech Republic
🇨🇿
Vojenska nemocnice Olomouc, Olomouc, Czech Republic

and more 43 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy